Tecnogen

Tecnogen is an Italian biotechnology company and research center that serves as the primary R&D hub for Alfasigma. Located in Piana di Monte Verna, the company specializes in the discovery and development of novel small molecules and biologics, with a strong historical emphasis on oncology and rare diseases. Tecnogen's capabilities include advanced molecular biology, medicinal chemistry, and high-throughput screening. The center has been instrumental in developing candidates such as gimatecan and namitecan, which target topoisomerase I. Today, it continues to support Alfasigma's therapeutic pipeline through innovative research and strategic collaborations.